CITROX BIOSCIENCES LIMITED

Financial Health Score: F (Critical Condition)

Citrox Biosciences Limited is exhibiting severe symptoms of financial distress. The company is technically insolvent with negative net assets, suffers from an acute liquidity crisis, and is currently kept alive on the financial equivalent of life support through heavy reliance on related-party creditors. Without immediate intervention to restore cash flow and restructure debt, the risk of formal insolvency proceedings is exceptionally high.

1. Key Vital Signs

• Cash Pulse (Cash at Bank): £9,493 (Up slightly from £103 in 2023, but down drastically from £492,973 in 2020). The company's cash reserves are dangerously low. With current liabilities of £1.37 million, this cash balance provides barely a heartbeat of operational runway.
• Working Capital (Net Current Assets): -£259,799 (Plummeted from a positive £84,260 in 2023). The business has negative working capital, meaning it owes more in short-term debts than it holds in short-term assets. This is a classic symptom of financial cardiac arrest.
• Solvency (Net Assets/Shareholders' Funds): -£122,681 (Dropped from -£19,205 in 2023 and a positive £672,381 in 2020). The company's liabilities now exceed its total assets. On the balance sheet, the patient is technically insolvent.
• Inventory Mass (Stocks): £769,019. While slightly down from the previous year, nearly half of the company's current assets are tied up in stock. If this inventory is slow-moving, it represents a severe blockage in the company's financial arteries, trapping vital cash.
• Intangible Asset Swelling: £465,354 (Up from £217,269). The company has invested heavily (£278,262 in additions) in patents and trademarks during the year. While this may indicate R&D activity, capitalizing these costs consumes cash and inflates the asset base without guaranteeing future revenue.

2. Diagnosis

The Underlying Condition: Citrox Biosciences is suffering from a chronic liquidity crisis compounded by negative equity. The financial data reveals a business that has burned through its historical cash reserves (£492k in 2020 down to £9k in 2024) to fund operations and R&D, resulting in a severe hemorrhage of working capital.

Related-Party Life Support: The most alarming symptom is the company's absolute dependence on related parties to stave off collapse. The accounts reveal that trade creditors include £164,295 owed to Oraldent Limited and £82,593 owed to Curaden (UK) Limited—both companies directed by Richard V M Thomas. Furthermore, short-term loans from Oraldent (£344,164) and Curaden (£50,000 due after one year), alongside £229,658 owed to Gelert Consulting Limited (also directed by R.V.M. Thomas), total over £600,000. These related-party creditors are acting as a financial ventilator; if they were to demand repayment, the company would immediately face fatal cash flow failure.

Asset Misalignment: The company has shifted its asset composition heavily toward intangible assets (patents/trademarks) and inventory, which together total £1.23 million—representing over 75% of total assets. Neither of these asset classes is easily or quickly convertible to cash, leaving the business starved of the liquid resources needed to pay immediate debts.

3. Prognosis

Guarded to Poor. The company's future health depends entirely on the continued forbearance of its related-party creditors and the successful commercialization of its intellectual property. The directors state that they consider the company a "going concern" based on available resources, but this prognosis relies heavily on the assumption that related parties will not call in their loans and that trade creditors will extend terms. The drop in employees from 4 to 3 suggests cost-cutting measures are underway, but the ongoing net losses indicate that the core business is not currently generating sufficient organic cash flow to sustain itself.

4. Recommendations

To stabilize the patient and restore financial wellness, the following immediate interventions are required:

1. Clear the Inventory Blockage: With £769k tied up in stock, an aggressive strategy must be implemented to convert inventory into cash. This may involve discounting, targeted sales campaigns, or liquidation. The business cannot afford to have the majority of its current assets sitting idle in a warehouse.
2. Restructure the Debt (Surgical Debt Reorganisation): The company must formally restructure its related-party debts. Converting the £344,164 short-term loan from Oraldent Limited and other associated debts into long-term liabilities (due after more than one year) would instantly improve net current assets and relieve the immediate cash flow pressure.
3. Halt the Cash Hemorrhage in R&D: While investment in patents is essential for a bioscience firm, capitalizing £278k in intangibles while the cash balance sits at £9k is a dangerous gamble. The company must evaluate whether current R&D expenditure can be slowed or funded through alternative means (such as grants or joint ventures) until the commercialization of existing IP begins generating revenue.
4. Equity Transfusion: The negative shareholders' funds (-£122k) need to be repaired. The related-party shareholders (Omni Dental Sciences, Infection Control Enterprise, and Howard Thomas) should consider a formal capital injection or converting existing director loans into equity to shore up the balance sheet and provide a buffer against future losses.